Foundations of Bariatric and Metabolic Surgery
Seance of wednesday 27 may 2026 (Chirurgie bariatrique: l'Académie reçoit la SOFFCO-MM - La chirurgie métabolique et bariatrique à l’ère des nouvelles thérapies médicamenteuses)
DOI number : 10.26299/4v3f-kv22/emem.2026.22.02
Abstract
Bariatric and metabolic surgery is built upon pathophysiological, organizational, and clinical foundations that make it a model for modern obesity medicine.
From a pathophysiological standpoint, the mechanisms of action extend far beyond gastric restriction. Anatomical reconfiguration triggers a reprogramming of the gut-brain axis, with massive secretion of anorexigenic peptides (GLP-1, PYY), microbiota modification, and improved insulin sensitivity. These mechanisms, first revealed through surgery, have since been validated by the development of new pharmacological treatments targeting the same pathways.
On the organizational level, France has established a rigorous framework: 2024 HAS clinical guidelines, specific authorization decrees with a minimum activity threshold of 50 procedures per site per year, mandatory multidisciplinary concertation, and structured lifelong follow-up.
Regarding long-term outcomes, the evidence is robust: sustained significant weight loss at 20 years (Carlson, NEJM 2020), dramatic reduction in type 2 diabetes complications (5% vs 73%, Mingrone, Lancet 2021), a 6-year gain in life expectancy (Syn, Lancet 2021), and MASH resolution. Revisional surgery represents a growing challenge, with revision rates reaching 60% at 15 years for gastric banding (national PMSI data).
Bariatric and metabolic surgery currently represents the therapeutic strategy for obesity with the highest level of evidence.
From a pathophysiological standpoint, the mechanisms of action extend far beyond gastric restriction. Anatomical reconfiguration triggers a reprogramming of the gut-brain axis, with massive secretion of anorexigenic peptides (GLP-1, PYY), microbiota modification, and improved insulin sensitivity. These mechanisms, first revealed through surgery, have since been validated by the development of new pharmacological treatments targeting the same pathways.
On the organizational level, France has established a rigorous framework: 2024 HAS clinical guidelines, specific authorization decrees with a minimum activity threshold of 50 procedures per site per year, mandatory multidisciplinary concertation, and structured lifelong follow-up.
Regarding long-term outcomes, the evidence is robust: sustained significant weight loss at 20 years (Carlson, NEJM 2020), dramatic reduction in type 2 diabetes complications (5% vs 73%, Mingrone, Lancet 2021), a 6-year gain in life expectancy (Syn, Lancet 2021), and MASH resolution. Revisional surgery represents a growing challenge, with revision rates reaching 60% at 15 years for gastric banding (national PMSI data).
Bariatric and metabolic surgery currently represents the therapeutic strategy for obesity with the highest level of evidence.